Jubilant Ingrevia Ltd
Jubilant Ingrevia Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward. Jubilant Ingrevia aims for at least 20% year-on-year growth in EBITDA for the full year FY27.
From Jubilant Ingrevia Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward.
- Specialty Chemicals and Nutrition segments are projected to lead growth, supported by volume recovery and price stability.
- CDMO business is poised for nonlinear growth, targeting 3x to 4x scaling over the Pinnacle Journey, driven by multiple innovative molecules in agro, pharma, and personal care.
- The large agro contract and other multi-year contracts provide visibility for steady or improved volumes, though some customer volume finalizations remain pending due to market volatility.
- Pipeline of 100+ opportunities with Rs. 3,500 crore potential in CDMO, including phased growth (20-25% peak revenue in Year 1, 50-60% in Year 2, 80%+ in Year 3).
- Nutrition business, notably Human Nutrition premixes, expected to grow rapidly post recent acquisition.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jubilant Ingrevia Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY27, Jubilant Ingrevia plans capex in the range of INR 400 crore to INR 500 crore to support growth.
- The significant portion of capex will be directed towards the Gajraula Multi-purpose Plant (MPP), expected to commence production in Q4 FY27.
- The company has recently capitalized its CDMO plant in March, leading to a reduction in capital work-in-progress.
- Continued investments align with the Pinnacle growth journey and are aimed at fueling expansion in Fine Chemicals, CDMO, Nutrition, and Specialty segments.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Ingrevia Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Jubilant Ingrevia currently has over 100 CDMO opportunities with a potential of approximately Rs. 3,500 crore.
- There are 20+ confirmed molecules and an additional pipeline of 10+ advanced stage molecules with a peak potential of Rs. 1,100 crore.
- The company secured a significant $300 million CDMO contract started shipping in March FY26, which forms a major pillar for growth in the current year.
- The overall CDMO order book is around Rs. 1,500 crore with various projects at different stages of development.
- New molecules are added every quarter; recent additions include 8 new molecules on top of 15 announced previously.
2 more points management made on order book & pipeline
Jubilant Ingrevia Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹86 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Ingrevia Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
- Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…
- Sudarshan Pharma Industries Ltd (Q4 FY26)
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…
- Innovassynth Technologies (India) Ltd (Q4 FY26)
Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…
Frequently Asked Questions
What were Jubilant Ingrevia Ltd Q4 FY26 results?
The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward. Jubilant Ingrevia aims for at least 20% year-on-year growth in EBITDA for the full year FY27.
What is Jubilant Ingrevia Ltd share price analysis?
Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 36.9 with a market cap of ₹11,738 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrevia Ltd planning capital expenditure?
For FY27, Jubilant Ingrevia plans capex in the range of INR 400 crore to INR 500 crore to support growth.
Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.